View ValuationKamada 향후 성장Future 기준 점검 2/6Kamada (는) 각각 연간 13.9% 및 8% 수익과 수익이 증가할 것으로 예상됩니다.핵심 정보13.9%이익 성장률n/aEPS 성장률Biotechs 이익 성장36.3%매출 성장률8.0%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트17 Apr 2026최근 향후 성장 업데이트Kamada Ltd. Affirms Earnings Guidance for the Year 2025; Provides Earnings Guidance for the Year 2026Jan 07Kamada Ltd. Reiterates Earnings Guidance for the Full Year 2025Nov 11Kamada Ltd. Reiterates Revenue Guidance for Full-Year 2025Aug 14Kamada Ltd. Reaffirms Financial Guidance for the Year 2025May 15Kamada Ltd. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Year 2025Jan 08Kamada Ltd. Provides Earnings Guidance for the Year 2024Aug 15모든 업데이트 보기Recent updatesKamada Ltd. Announces FDA Approval Of Plasma Collection Center In San Antonio, TexasMar 27Full year 2025 earnings released: EPS: US$0.35 (vs US$0.25 in FY 2024) Mar 12Kamada Ltd. Declares Annual Cash Dividend, Payable on April 6, 2026Mar 11+ 1 more updateKamada Ltd. to Report Q4, 2025 Results on Mar 11, 2026Mar 05Kamada Ltd. Affirms Earnings Guidance for the Year 2025; Provides Earnings Guidance for the Year 2026Jan 07Kamada Announces Discontinuation of Its Phase 3 Inhaled AAT Clinical TrialDec 09Shareholders May Not Be So Generous With Kamada Ltd.'s (TLV:KMDA) CEO Compensation And Here's WhyDec 04Kamada's (TLV:KMDA) Performance Is Even Better Than Its Earnings SuggestNov 21Third quarter 2025 earnings released: EPS: US$0.09 (vs US$0.07 in 3Q 2024) Nov 11Kamada Ltd. Reiterates Earnings Guidance for the Full Year 2025Nov 11Kamada Ltd. Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of Cytogam®? to Prevent Cytomegalovirus in Kidney TransplantationNov 06Kamada Ltd. to Report Q3, 2025 Results on Nov 10, 2025Nov 03Kamada Ltd., Annual General Meeting, Dec 10, 2025Oct 24Second quarter 2025 earnings released: EPS: US$0.13 (vs US$0.08 in 2Q 2024) Aug 14Kamada Ltd. Reiterates Revenue Guidance for Full-Year 2025Aug 14Kamada Ltd. Announces FDA Approval of its Plasma Collection Center in Houston, TexasAug 12Kamada Ltd. to Report Q2, 2025 Results on Aug 13, 2025Aug 06Kamada's (TLV:KMDA) Solid Earnings Are Supported By Other Strong FactorsMay 22First quarter 2025 earnings released: EPS: US$0.07 (vs US$0.04 in 1Q 2024) May 15Kamada Ltd. Reaffirms Financial Guidance for the Year 2025May 15Kamada Ltd. to Report Q1, 2025 Results on May 14, 2025May 07Kamada Ltd. Announces Launch of Comprehensive Post-Marketing Research Program for CYTOGAMMay 06New minor risk - Earnings quality Mar 06Kamada Declares Special Cash Dividend, Payable on April 7, 2025Mar 06+ 1 more updateKamada Ltd. to Report Q4, 2024 Results on Mar 05, 2025Feb 26New minor risk - Share price stability Feb 10Investor sentiment improves as stock rises 26% Feb 10Market Participants Recognise Kamada Ltd.'s (TLV:KMDA) Earnings Pushing Shares 25% HigherJan 11Investor sentiment improves as stock rises 15% Jan 09Kamada Ltd. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Year 2025Jan 08Here's Why Shareholders May Want To Be Cautious With Increasing Kamada Ltd.'s (TLV:KMDA) CEO Pay PacketDec 05Solid Earnings Reflect Kamada's (TLV:KMDA) Strength As A BusinessNov 20Third quarter 2024 earnings released: EPS: US$0.07 (vs US$0.07 in 3Q 2023) Nov 16Kamada Ltd. to Report Q3, 2024 Results on Nov 13, 2024Nov 06Kamada Ltd., Annual General Meeting, Dec 11, 2024Oct 22Second quarter 2024 earnings released: EPS: US$0.08 (vs US$0.04 in 2Q 2023) Aug 15Kamada Ltd. Provides Earnings Guidance for the Year 2024Aug 15Kamada Ltd. to Report Q2, 2024 Results on Aug 14, 2024Aug 07First quarter 2024 earnings released May 09Kamada Ltd. Raises Earnings Guidance for the Year 2024May 09Kamada Ltd. to Report Q1, 2024 Results on May 08, 2024May 03Kamada's (TLV:KMDA) Earnings Are Of Questionable QualityMar 14Full year 2023 earnings released: EPS: US$0.17 (vs US$0.052 loss in FY 2022) Mar 07Kamada Ltd. Provides Revenue Guidance for the Year 2024Mar 06Kamada Ltd. to Report Q4, 2023 Results on Mar 06, 2024Feb 29Kamada Ltd. (TLV:KMDA) Held Back By Insufficient Growth Even After Shares Climb 29%Dec 30Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This YearDec 22Investor sentiment improves as stock rises 19% Dec 06Third quarter 2023 earnings released: EPS: US$0.07 (vs US$0.011 in 3Q 2022) Nov 14Kamada Ltd., Annual General Meeting, Dec 28, 2023Nov 14Kamada Ltd. to Report Q3, 2023 Results on Nov 13, 2023Nov 09Kamada Ltd. Announces Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical DataOct 17New minor risk - Shareholder dilution Sep 09Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2023Aug 17Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.09 loss in 2Q 2022) Aug 17Kamada Ltd. to Report Q2, 2023 Results on Aug 16, 2023Aug 10First quarter 2023 earnings released: US$0.04 loss per share (vs US$0.04 loss in 1Q 2022) May 26Kamada Ltd. announced that it expects to receive $59.85 million in funding from First Israel Mezzanine Investors Ltd.May 25+ 3 more updatesKamada Ltd. to Report Q1, 2023 Results on May 24, 2023May 19Kamada Ltd. Announces Receipt of Marketing Authorization for Glassia for Treatment of Alpha-1 Antitrypsin Deficiency in SwitzerlandMay 17Kamada Ltd. Announces U.S. FDA Approval of Its Application to Manufacture CYTOGAM At the Company’s Facility in IsraelMay 04Full year 2022 earnings released: US$0.05 loss per share (vs US$0.05 loss in FY 2021) Mar 16Is Kamada (TLV:KMDA) Using Too Much Debt?Jan 26Kamada Ltd. Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® At the Company’s Facility in IsraelJan 05Kamada Ltd. Appoints Uri Botzer as Members of Board of DirectorsDec 23Kamada Announces Planned Transition of Chaime Orlev, Chief Financial Officer, Effective March 15, 2023Dec 20We Discuss Why Kamada Ltd.'s (TLV:KMDA) CEO Compensation May Be Closely ReviewedDec 16Third quarter 2022 earnings released: EPS: US$0.01 (vs US$0.02 loss in 3Q 2021) Nov 23Kamada Ltd. Provides Revenue Guidance for the Fiscal Year 2022Nov 23Kamada Ltd. to Report Q3, 2022 Results on Nov 22, 2022Nov 17High number of new directors Nov 16Kamada Ltd., Annual General Meeting, Dec 22, 2022Nov 09Kamada Ltd. Updates on Recent Progress Achieved in Ongoing Pivotal Phase 3 InnovAATe Clinical TrialNov 08Second quarter 2022 earnings released: US$0.09 loss per share (vs US$0.02 profit in 2Q 2021) Aug 18Kamada Ltd. Provides Earnings Guidance for the Second Half of Year and Full Year 2022Aug 18Kamada Ltd. to Report Q2, 2022 Results on Aug 17, 2022Aug 11Kamada Ltd. Provides Earnings Guidance for the Full Year of 2022Jun 02First quarter 2022 earnings released: US$0.04 loss per share (vs US$0.06 profit in 1Q 2021) May 19Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2022May 19Kamada Ltd. Updates on Recent Progress Achieved in Its Ongoing Pivotal Phase 3 InnovAATe Clinical Trial Evaluating the Safety and Efficacy of Proprietary Inhaled Alpha-1 Antitrypsin Therapy for the Treatment of Alpha-1 Antitrypsin DeficiencyMay 18Kamada Ltd. to Report Q1, 2022 Results on May 17, 2022May 12High number of new directors Apr 27Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 15Kamada Ltd. to Report Q4, 2021 Results on Mar 15, 2022Mar 04Kamada Ltd. Acquires Portfolio of Four Plasma-Derived Hyperimmune Commercial Products from Saol TherapeuticsNov 24Third quarter 2021 earnings: EPS in line with expectations, revenues disappoint Nov 23Kamada Ltd.(TASE:KMDA) dropped from TA-125 IndexAug 14Second quarter 2021 earnings released: EPS US$0.02 (vs US$0.08 in 2Q 2020) Aug 13Kedrion Biopharma and Kamada Ltd. Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in ChildrenJun 03First quarter 2021 earnings released: EPS US$0.06 (vs US$0.12 in 1Q 2020) May 13Kamada Ltd. (TASE:KMDA) completed the acquisition of Plasma collection center and certain related rights and assets from Blood and Plasma Research, Inc.Mar 05New 90-day low: ₪20.12 Mar 02Investors Who Bought Kamada (TLV:KMDA) Shares Five Years Ago Are Now Up 38%Mar 01Full year 2020 earnings released: EPS US$0.39 (vs US$0.55 in FY 2019) Feb 11이익 및 매출 성장 예측TASE:KMDA - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20282414045N/A212/31/2027228363640312/31/2026209302231412/31/2025180201625N/A9/30/2025175201828N/A6/30/2025170193240N/A3/31/2025167163746N/A12/31/2024161143748N/A9/30/2024158163242N/A6/30/2024155151120N/A3/31/20241501218N/A12/31/20231438-24N/A9/30/2023152627N/A6/30/20231463611N/A3/31/2023132-21620N/A12/31/2022129-22529N/A9/30/2022115-101317N/A6/30/2022106-1259N/A3/31/2022107-7-10-5N/A12/31/2021104-2-13-9N/A9/30/2021104449N/A6/30/20211161249N/A3/31/2021125151823N/A12/31/2020133171419N/A9/30/2020134211115N/A6/30/2020132202023N/A3/31/2020134231720N/A12/31/2019127222528N/A9/30/201914335N/A25N/A6/30/201912526N/A20N/A3/31/201912426N/A11N/A12/31/201811422N/A11N/A9/30/201810211N/A8N/A6/30/201811013N/A5N/A3/31/201810912N/A8N/A12/31/20171037N/A4N/A9/30/201791-1N/A2N/A6/30/201788-2N/A2N/A3/31/201774-8N/A-5N/A12/31/201677-7N/A2N/A9/30/201679-4N/A-6N/A6/30/201676-8N/A-5N/A3/31/201676-8N/A-5N/A12/31/201570-11N/A-14N/A9/30/201569-11N/A-8N/A6/30/201570-9N/A-12N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: KMDA 의 연간 예상 수익 증가율(13.9%)이 saving rate(3.3%)보다 높습니다.수익 vs 시장: KMDA 의 연간 수익(13.9%)이 IL 시장(11.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: KMDA 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: KMDA 의 수익(연간 8%)이 IL 시장(연간 9.6%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: KMDA 의 수익(연간 8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: KMDA의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/01 08:29종가2026/05/01 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Kamada Ltd.는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Robert WassermanBenchmark CompanyAndrew FeinH.C. Wainwright & Co.Anthony PetroneJefferies LLC5명의 분석가 더 보기
Kamada Ltd. Affirms Earnings Guidance for the Year 2025; Provides Earnings Guidance for the Year 2026Jan 07
Kamada Ltd. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Year 2025Jan 08
Kamada Ltd. Affirms Earnings Guidance for the Year 2025; Provides Earnings Guidance for the Year 2026Jan 07
Shareholders May Not Be So Generous With Kamada Ltd.'s (TLV:KMDA) CEO Compensation And Here's WhyDec 04
Kamada Ltd. Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of Cytogam®? to Prevent Cytomegalovirus in Kidney TransplantationNov 06
Kamada Ltd. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Year 2025Jan 08
Here's Why Shareholders May Want To Be Cautious With Increasing Kamada Ltd.'s (TLV:KMDA) CEO Pay PacketDec 05
Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This YearDec 22
Kamada Ltd. Announces Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical DataOct 17
Kamada Ltd. announced that it expects to receive $59.85 million in funding from First Israel Mezzanine Investors Ltd.May 25+ 3 more updates
Kamada Ltd. Announces Receipt of Marketing Authorization for Glassia for Treatment of Alpha-1 Antitrypsin Deficiency in SwitzerlandMay 17
Kamada Ltd. Announces U.S. FDA Approval of Its Application to Manufacture CYTOGAM At the Company’s Facility in IsraelMay 04
Kamada Ltd. Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® At the Company’s Facility in IsraelJan 05
Kamada Announces Planned Transition of Chaime Orlev, Chief Financial Officer, Effective March 15, 2023Dec 20
Kamada Ltd. Updates on Recent Progress Achieved in Ongoing Pivotal Phase 3 InnovAATe Clinical TrialNov 08
Kamada Ltd. Updates on Recent Progress Achieved in Its Ongoing Pivotal Phase 3 InnovAATe Clinical Trial Evaluating the Safety and Efficacy of Proprietary Inhaled Alpha-1 Antitrypsin Therapy for the Treatment of Alpha-1 Antitrypsin DeficiencyMay 18
Kamada Ltd. Acquires Portfolio of Four Plasma-Derived Hyperimmune Commercial Products from Saol TherapeuticsNov 24
Kedrion Biopharma and Kamada Ltd. Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in ChildrenJun 03
Kamada Ltd. (TASE:KMDA) completed the acquisition of Plasma collection center and certain related rights and assets from Blood and Plasma Research, Inc.Mar 05